1.Study on fluvoxamine maleate sustained-release pellets and its compression technology
Ming-hui XU ; Xing-yue ZHANG ; Qiao DONG ; Xia ZHAO ; Yu-ru BU ; Le-zhen CHEN
Acta Pharmaceutica Sinica 2024;59(2):439-447
		                        		
		                        			
		                        			 In this study, fluvoxamine maleate sustained-release pellet system tablets were prepared and were used to evaluate their release behaviors
		                        		
		                        	
4.Meta-Analysis for Effect of Danhong Injection on Cardiac Function and TIMI During Perioperative PCI in Acute Myocardial Infarction
Meng-chen YUAN ; Yong-hong GAO ; Jie WANG ; Bu-chang ZHAO ; Yan-wei XING ; Jun LI ; Heng-wen CHEN ; Tao ZHAO ; Chao ZHAO ; Yi-min WANG
Chinese Journal of Experimental Traditional Medical Formulae 2020;26(1):178-183
		                        		
		                        			
		                        			Objective::Evaluate the effects of Danhong injection for perioperative percutaneous coronary intervention (PCI) on cardiac function and thrombolysis in myocardial infarction (TIMI) in patients with acute myocardial infarction (AMI).  Method::Computer retrieving CNKI, Wanfang database, VIP database, PubMed, CBM, Web of Science, The Cochrane Library, gathering Danhong injection in percutaneous coronary intervention perioperative application in the treatment of acute myocardial infarction clinic trials. The Cochrane risk evaluation is adopted to improve the quality of literature evaluation, with Revman 5.3 software for Meta-analysis.  Result::Participants included in 12 clinic trials contains a total of 1 131 patients, including 569 patients in Danhong treatment and 562 patients in control group. The results showed that compared with conventional treatment, Danhong injection treated patients had LVEF increased obviously [mean difference (MD)=6.62, 95% confidence interval (CI) (4.91, 8.34), 
		                        		
		                        	
5.Regulation of FN1 degradation by the p62/SQSTM1-dependent autophagy-lysosome pathway in HNSCC.
Xinchen LIU ; Lin MENG ; Xing LI ; Daowei LI ; Qilin LIU ; Yumeng CHEN ; Xiangwei LI ; Wenhuan BU ; Hongchen SUN
International Journal of Oral Science 2020;12(1):34-34
		                        		
		                        			
		                        			Epithelial-mesenchymal transition (EMT) is involved in both physiological and pathological processes. EMT plays an essential role in the invasion, migration and metastasis of tumours. Autophagy has been shown to regulate EMT in a variety of cancers but not in head and neck squamous cell carcinoma (HNSCC). Herein, we investigated whether autophagy also regulates EMT in HNSCC. Analyses of clinical data from three public databases revealed that higher expression of fibronectin-1 (FN1) correlated with poorer prognosis and higher tumour pathological grade in HNSCC. Data from SCC-25 cells demonstrated that rapamycin and Earle's balanced salt solution (EBSS) promoted autophagy, leading to increased FN1 degradation, while 3-methyladenine (3-MA), bafilomycin A1 (Baf A1) and chloroquine (CQ) inhibited autophagy, leading to decreased FN1 degradation. On the other hand, autophagic flux was blocked in BECN1 mutant HNSCC Cal-27 cells, and rapamycin did not promote autophagy in Cal-27 cells; also in addition, FN1 degradation was inhibited. Further, we identified FN1 degradation through the lysosome-dependent degradation pathway using the proteasome inhibitor MG132. Data from immunoprecipitation assays also showed that p62/SQSTM1 participated as an autophagy adapter in the autophagy-lysosome pathway of FN1 degradation. Finally, data from immunoprecipitation assays demonstrated that the interaction between p62 and FN1 was abolished in p62 mutant MCF-7 and A2780 cell lines. These results indicate that autophagy significantly promotes the degradation of FN1. Collectively, our findings clearly suggest that FN1, as a marker of EMT, has adverse effects on HNSCC and elucidate the autophagy-lysosome degradation mechanism of FN1.
		                        		
		                        		
		                        		
		                        			Autophagy
		                        			;
		                        		
		                        			Cell Line, Tumor
		                        			;
		                        		
		                        			Female
		                        			;
		                        		
		                        			Fibronectins
		                        			;
		                        		
		                        			Humans
		                        			;
		                        		
		                        			Lysosomes/metabolism*
		                        			;
		                        		
		                        			Ovarian Neoplasms
		                        			;
		                        		
		                        			Sequestosome-1 Protein/metabolism*
		                        			;
		                        		
		                        			Squamous Cell Carcinoma of Head and Neck
		                        			
		                        		
		                        	
6. Mechanism and Clinical Efficacy of Danhong Injection in Treatment of Coronary Heart Disease
Jie WANG ; Tao ZHAO ; Xing-jiang XIONG ; Chao ZHAO ; Bo FENG ; Jing-yi WANG ; Chao LIU ; Heng-wen CHEN ; Yi-min WANG ; Bu-chang ZHAO
Chinese Journal of Experimental Traditional Medical Formulae 2019;25(24):173-178
		                        		
		                        			
		                        			 Coronary heart disease (CHD) is one of the leading causes of death in the world and has become a major public health problem worldwide. CHD belongs to the category of "chest stuffiness" in traditional Chinese medicine, and the blood stasis syndrome is the most common syndrome.Danhong injection is prepared from the extract of Salviae Miltiorrhizae Radix et Rhizoma and Carthami Flos. It has the functions of promoting blood circulation and removing blood stasis. It has anti-inflammatory damage, anti-apoptosis, protection of vascular endothelium, inhibition of platelet aggregation, anti-hyperlipidemia, anticoagulation, improvement of blood rheology and other effects.It also could improve myocardial ischemia and relieve angina symptoms.Danhong injection is widely used in various stages of CHD, including stable angina pectoris, unstable angina pectoris, acute myocardial infarction, postoperative percutaneous coronary intervention(PCI), ischemic cardiomyopathy, CHD with arrhythmia, CHD with hyperlipidemia, CHD with heart failure and CHD with diabetes. 
		                        		
		                        		
		                        		
		                        	
7.Preliminary investigation on mechanism of Naoxintong capsule's preventive treatment of cardio-cerebrovascular disease based on serum proteomics.
Xiao GENG ; Lu CHEN ; Bu-Chang ZHAO ; Chun-Xiao LI ; Li-Zhen QIU ; Xing-Yu YOU ; Yi-Min WANG ; Lu-Sha ZHANG ; Hong WANG
China Journal of Chinese Materia Medica 2016;41(15):2864-2871
		                        		
		                        			
		                        			Naoxintong capsule has beneficial effects for activating blood circulation, dispersing blood stasis and dredging collateral. It is widely used in the treatment of coronary heart disease, angina pectoris, stroke and cardiovascular disease. However, the pharmacodynamic basis and possible mechanism of its preventive effects are not clear. In this study, 10 male and 10 female C57BL/6 mice were used, and were randomly divided into the control group (saline) and Naoxintong group. Adaptively fed for 7 days in common conditions, mice were given Naoxintong capsule or saline for 3 days via intragastric administration. Serum was collected from 6 mice in each group 1 h after the last administration. Serum proteins were prepared to do two-dimensional gel electrophoresis. Then image analysis and mass spectrometry detection were carried out to screen and identify the differentially expressed proteins and make bioinformatics analysis. It was found that 24 differentially expressed proteins between Naoxintong group and control group. Compared with the control group, 12 proteins were increased, and 12 were decreased. The proteins were involved in apoptosis signal pathway and vascular endothelial growth factor signal transduction pathway, in which vasohibin-1 is a negative feedback regulation factor in angiogenesis. Western blot showed that the expression of vasohibin-1 in Naoxintong group was reduced, which is consistent with the result in two-dimensional electrophoresis. Serum proteins expression is different between Naoxintong and control groups. The targets of these differentially expressed proteins include endothelial cells, inflammatory cells and platelets. The changes on proteins showed that Naoxintong capsule may ameliorate coronary heart disease and ischemic cerebrovascular disease, and provide potential biological markers to prevent ischemic disease.
		                        		
		                        		
		                        		
		                        	
8.Performance measures for management of chronic heart failure patients with acute coronary syndrome in China: results from the Bridging the Gap on Coronary Heart Disease Secondary Prevention in China (BRIG) Project.
Na WANG ; Dong ZHAO ; Jing LIU ; Jun LIU ; Cheuk-man YU ; Wei WANG ; Jia-yi SUN ; Yan LI ; Bu-xing CHEN ; null
Chinese Medical Journal 2013;126(14):2625-2631
BACKGROUNDChronic heart failure (CHF) is a severe clinical syndrome associated with high morbidity and mortality, and with high health care expenditures. No nationwide data are currently available regarding the quality of clinical management of CHF patients in China. The aim of this study was to assess the quality of care of CHF inpatients in China.
METHODSThe American College of Cardiology/American Heart Association Clinical Performance Measures for Adults with Chronic Heart Failure (Inpatient Measurement Set) with slight modifications was used to measure the performance status in 612 CHF patients with acute coronary syndrome (ACS) from 65 hospitals across all regions of China.
RESULTSThe implementation rates of guideline recommended strategies for CHF management were low. Only 57.5% of the CHF patients received complete discharge instructions, 53.6% of the patients received evaluation of left ventricular systolic function, 62.8% received an angiotensin-converting enzyme inhibitor/angiotensin receptor blocker at discharge, and 52.7% received a β-blocker at discharge, 56.3% of the smokers received smoking cessation counseling. The rate of warfarin utilization was only 9.7% in CHF patients with atrial fibrillation. Most patients (81.4%) did not receive all the first four treatments. There were marked differences in the quality of CHF management among patients with different characteristics.
CONCLUSIONSPerformance measures provide a standardized method of assessing quality of care, and can thus highlight problems in disease management in clinical practice. The quality of care for CHF patients with ACS in China needs to be improved.
Acute Coronary Syndrome ; therapy ; Aged ; China ; Female ; Heart Failure ; therapy ; Humans ; Male ; Middle Aged ; Quality of Health Care ; Secondary Prevention ; Sex Characteristics
9.A case report of very late thrombosis in two sirolimus-eluting stents.
Chinese Journal of Cardiology 2010;38(12):1131-1134
10.Using the combination of traditional risk factors and quantitative coronary angiography (QCA )in predicting the risk of individuals with subclinical artherosclerosis
Guo-Zhong WANG ; Shu-Zheng LV ; Jing-Hua LIU ; Yun-Dai CHEN ; Yong HUO ; Wei GAO ; Wei-Min WANG ; Fang CHEN ; Yu-Jie ZHOU ; Zhi-Zhong LI ; Yuan-Nan KE ; Xin-Chun YANG ; Shu-Yang ZHANG ; Hong-Bing YAN ; Hong-Wei LI ; Da-Zhuo SHI ; Bu-Xing CHEN
Chinese Journal of Epidemiology 2010;31(12):1383-1388
		                        		
		                        			
		                        			Objective To determine whether the combination of traditional risk factors and quantitative coronary angiography (QCA) assessment could provide accurate prognostic information on a population-based study including 1137 adults with subclinical artherosclerosis and with coronary risk factors. Methods Participants underwent coronary angiography examination before the minimal stenotic diameters, segment diameters, percent stenosis, plaque areas. Other parameters were analyzed by the computer-assisted Coronary Angiography Analysis System. The Framingham Risk Score for each participant was assessed. During the 1 year follow-up period, all kinds of endpoint cardiovascular events were screened. Endpoint events were defined as death from coronary heart disease, nonfatal myocardial infarction (MI) or unstable angina pectoris. Results During the 1 year of follow-up period, a total of 124 participants developed an endpoint event, which was significantly associated with the Framingham Risk Score, calcium of plaques and the plaque areas (all Ps<0.05).The QCA score incorporated with the QCA parameters was related to the endpoint events. The Framingham Risk Score was combined with QCA score through logistic regression for prediction of end-point events. Data from the ROC analysis showed the accuracy of this prediction algorithm was superior to the accuracy when variables themselves were used. The event-free survival rate was inferior to the control group in participates under high risk, when being screened with this prediction algorithm (P<0.05). Conclusion The risk of cardiovascular attack in subclinical artherosclerosis individual seemed to be associated with the Framingham Risk Score, calcium of plaques and the plaque areas. When the traditional risk factors (the Framingham Risk Score) were combined with QCA, the new method could provide more prognostic information on those adults with subclinical artherosclerosis.
		                        		
		                        		
		                        		
		                        	
            
Result Analysis
Print
Save
E-mail